Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

O&G VivasGynaecological oncology — screening and prevention

O&G Vivas · Gynaecological oncology — screening and prevention

Cervical screening and HPV — structured oral station (12 minutes)

FRANZCOG oral-format station on cervical screening: the candidate explains the NCSP eligibility and self-collection policy, navigates the reflex cytology triage pathway, defends the post-LLETZ test of cure, and counsels on the rationale for the start age and the obstetric harms of over-treatment. Scored against the eight published RANZCOG oral domains.

clinical3 min readVerification in progress

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI
On this page
Study tools

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI
Prompt
You are the GP registrar seeing a 35-year-old woman, para 1, who has not had a cervical screen for 10 years. She is anxious about speculum examination and asks whether she can 'do the test herself'. Her self-collected Cervical Screening Test returns positive for HPV type 16. The examiner will ask you to explain the NCSP and self-collection, defend the next step, reproduce the reflex cytology triage pathway, discuss the obstetric consequences of over-treatment, and counsel the patient.

Station format

4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply to every station: history and examination; investigations and interpreting results; treatment and management; clinical knowledge; complex, urgent or unusual clinical presentations; rapport with patient, support person or colleague; respect; communication skills. You are marked on how you behave, not only what you know. [1]

Reveal the examiner script and model responsesShowHide

Opening prompt — "She is anxious and asks whether self-collection is real. What do you tell her?"

Model response — reassure with the evidence: [1][2]

  • "Yes. Since 1 July 2022, all women and people with a cervix aged 25 to 74 in the NCSP can self-collect a vaginal sample, in clinic or at home. You can do it in a private space here today if you like."
  • "Self-collection is as accurate as clinician-collection for detecting HPV when validated PCR-based assays are used — the Arbyn 2022 meta-analysis confirmed high concordance between the two methods. If HPV is detected, you will need a follow-up clinician-collected sample for cytology, or a direct referral to colposcopy depending on the HPV type."[1][2]

Probe 1 — "Her result returns positive for HPV 16. Reflex cytology could not be performed on the self-collected sample. What is the next step?"

  • "Refer to colposcopy. HPV 16 is referred to colposcopy regardless of the reflex cytology result."
  • "Because reflex cytology could not be performed on the self-collected sample, I would also arrange a clinician-collected sample at the colposcopy visit, so the cytology can be reviewed alongside the colposcopic impression." [1]

Probe 2 — "Reproduce the reflex cytology triage pathway for a clinician-collected HPV-positive sample."

  • "HPV not detected — return to 5-yearly routine screening."
  • "HPV 16 or 18 detected — refer colposcopy regardless of reflex cytology."
  • "Other high-risk HPV with pHSIL, HSIL or greater on reflex cytology — refer colposcopy."
  • "Other high-risk HPV with LSIL or negative reflex cytology — repeat HPV test in 12 months; if still positive at 12 months, refer colposcopy." [1]

Probe 3 — "Colposcopy confirms CIN 3 and she undergoes LLETZ with clear margins. What surveillance does she need?"

  • "Post-treatment HPV surveillance per the current NCSP test-of-cure pathway is the test of cure — I would confirm the interval and stopping rule in the current guideline. If negative, return to routine screening; if positive, refer back to colposcopy." [1]

Probe 4 — "Why does the NCSP start screening at 25 rather than 18 or 20?"

  • "Three reasons: very low cancer incidence under 25 (about 1 to 2 percent of cases); high HPV clearance in young women (most infections clear within 1 to 2 years, so screening generates many false positives); and the obstetric harms of over-treatment — excision of CIN 2/3 increases preterm birth, premature rupture of membranes and low birthweight (Kyrgiou 2016), with no benefit for CIN that would have regressed. HPV vaccination of adolescents has further reduced the yield of screening under 25." [3]
  • "The one exception is a symptomatic young woman — postcoital or persistent intermenstrual bleeding, or a visible lesion — who needs diagnostic colposcopy at any age, regardless of the screening start age." [1]

Probe 5 — Communication probe: "She asks whether her 13-year-old daughter should get the HPV vaccine. What do you say?"

This is a scored communication domain — demonstrate it out loud: [4]

  • "Yes, absolutely. The 9-valent HPV vaccine is given as a single dose for immunocompetent people from 9 to 25 years; three doses are reserved for the severely immunocompromising at any age."[5]
  • "Even vaccinated, your daughter will still need screening from age 25."[1][5]
Obstetrics & Gynaecology Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]Smith M, Hammond I, Saville M, et al. Lessons from the renewal of the National Cervical Screening Program in Australia. Public Health Res Pract, 2019.PMID 31384888
  2. [2]Arbyn M, Castle PE, Schiffman M, et al. Meta-analysis of agreement/concordance statistics in studies comparing self- vs clinician-collected samples for HPV testing in cervical cancer screening. Int J Cancer, 2022.PMID 35179777
  3. [3]Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ, 2016.PMID 27469988
  4. [4]Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health, 2019.PMID 30291040
  5. [5]Australian Technical Advisory Group on Immunisation Human papillomavirus (HPV) The Australian Immunisation Handbook, 2025.Source
Obstetrics & Gynaecology Pro

$29/ monthor $279 / year

The complete Obstetrics & Gynaecology library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousCervical cerclage — structured oral station (12 minutes)Gynae-surgery — cervical insufficiency and preterm birth preventionNextChronic pelvic pain — structured oral station (12 minutes)Gynaecological health — chronic pain